


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended): A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R¹ represents a group of formula -NR^aR^b or a nitrogen containing heterocyclyl group optionally substituted by one or more (eg. 1 to 4) C₁₋₆ alkyl groups;

X represents a bond, -(CR^cR^d)-, -(CR^cR^d)-(CR^eR^f)-, -(CR^cR^d)-(CR^eR^f)-(CR^gR^h)-, or -heterocyclyl-, wherein said heterocyclyl group may be optionally substituted by one or more (eg. 1 to 4) C₁₋₆ alkyl groups; such that when R¹ represents -NR^aR^b, X does not represent a bond nor -(CR^cR^d)-;

R^a, R^b, R^c, R^d, R^e, R^f, R^g and R^h independently represent hydrogen or C₁₋₆ alkyl;

R² represents halogen, cyano, -CF₃, -CF₃O, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl or a group -CONR⁵R⁶;

n represents 0 to 3;

R³ and R⁴ independently represent hydrogen, halogen, cyano, -CF₃, -CF₃O, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl or a group -CONR⁵R⁶;

R⁵ and R⁶ independently represent hydrogen or C₁₋₆ alkyl or together with the N atom to which they are attached may be fused to form a 5- to 7- membered N-containing aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

A represents an -aryl, -heteroaryl, -aryl-aryl, -aryl-heteroaryl, -heteroaryl-aryl or -heteroaryl-heteroaryl group;

wherein said aryl and heteroaryl groups of A may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C₁₋₆ alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C₁₋₆ alkoxy, arylC₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxyC₁₋₆ alkyl, C₃₋₇ cycloalkylC₁₋₆ alkoxy, C₁₋₆ alkanoyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylsulfonylC₁₋₆ alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC₁₋₆ alkyl, C₁₋₆ alkylsulfonamido, C₁₋₆ alkylamido, C₁₋₆ alkylsulfonamidoC₁₋₆ alkyl, C₁₋₆ alkylamidoC₁₋₆ alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC₁₋₆ alkyl, arylcarboxamidoC₁₋₆ alkyl, aroyl, aroylC₁₋₆ alkyl, arylC₁₋₆ alkanoyl, or a group CONR⁷R⁸ or SO₂NR⁷R⁸, wherein R⁷ and R⁸ independently represent hydrogen or C₁₋₆ alkyl or R⁷ and R⁸ together with the nitrogen atom to which they are attached may form a nitrogen containing heterocyclyl or heteroaryl group;
~~or solvates thereof.~~

2. (Original): A compound of formula (I) as defined in claim 1, wherein A represents aryl optionally substituted by one or more halogen atoms or heteroaryl.

3. (Currently amended): A compound of formula (I) as defined in claim 1 ~~or claim 2~~, wherein R¹ represents NR^aR^b, wherein R^a and R^b are independently hydrogen or methyl; or a nitrogen containing heterocyclyl group selected from pyrrolidinyl, piperidinyl, morpholinyl, azabicyclo[2.2.2]oct-3-yl or azepinyl optionally substituted by methyl or isopropyl.

4. (Original): A compound of formula (I) as defined in claim 1 selected from:
[2-(3-Phenylsulfonylquinoline-8-yloxy)ethyl]dimethylamine;
8-({[(2S)-1-Methyl-2-pyrrolidinyl]methyl}oxy)-3-(phenylsulfonyl) quinoline;
3-(Phenylsulfonyl)-8-{{[(2S)-2-pyrrolidinylmethyl]oxy} quinoline;
3-(Phenylsulfonyl)-8-{{[2-(1-pyrrolidinyl)ethyl]oxy} quinoline;
3-(Phenylsulfonyl)-8-[(3R)-3-pyrrolidinyl]oxy]quinoline;

Dimethyl(1-methyl-2-{[3-(phenylsulfonyl)-8-quinolinyl]oxy} propyl)amine;
3-(Phenylsulfonyl)-8- {[2(2R)-2-pyrrolidinylmethyl]oxy} quinoline;
3-(Phenylsulfonyl)-8- {[2-(1-piperidinyl)ethyl]oxy} quinoline;
8- {[2-(4-Morpholinyl)ethyl]oxy} -3-(phenylsulfonyl)quinoline;
8-(1-Azabicyclo[2.2.2]oct-3-yloxy)-3-(phenylsulfonyl)quinoline;
3-(Phenylsulfonyl)-8- {[3-(1-piperidinyl)propyl]oxy} quinoline;
8- {[2-(Hexahydro-1H-azepin-1-yl)ethyl]oxy} -3-(phenylsulfonyl)quinoline;
((3S,4R)-4- {[3-(Phenylsulfonyl)-8-quinolinyl]oxy} tetrahydro-3-furanyl)amine;
(3S,4R)-N,N-Dimethyl-4- {[3-(phenylsulfonyl)-8-quinolinyl]oxy} tetrahydro-3-furanamine;
3-(Phenylsulfonyl)-8-(3-piperidinyloxy)quinoline;
3-(Phenylsulfonyl)-8-(4-piperidinyloxy)quinoline;
8- {[3(3R)-1-Methyl-3-pyrrolidinyl]oxy} -3-(phenylsulfonyl)quinoline;
8- {[3(3S)-1-Methyl-3-pyrrolidinyl]oxy} -3-(phenylsulfonyl)quinoline;
8-[(3R)-1-Azabicyclo[2.2.2]oct-3-yloxy]-3-(phenylsulfonyl)quinoline;
3-(Phenylsulfonyl)-8-[(3S)-3-pyrrolidinyl]oxy]quinoline;
8-[(1-Methyl-4-piperidinyl)oxy]-3-(phenylsulfonyl)quinoline;
8-[(1-Azabicyclo[2.2.2]oct-2-ylmethyl)oxy]-3-(phenylsulfonyl)quinoline;
8-[(1-Methyl-3-piperidinyl)oxy]-3-(phenylsulfonyl)quinoline;
8-[(3-Morpholinylmethyl)oxy]-3-(phenylsulfonyl)quinoline;
8-([3(2S)-1-(1-Methylethyl)-2-pyrrolidinyl]methyl]oxy)-3-(phenylsulfonyl)quinoline;
N,N-Dimethyl-2- {[3-(phenylsulfonyl)-8-quinolinyl]oxy} -1-propanamine; or
5-Chloro-3-(phenylsulfonyl)-8- {[2-(1-pyrrolidinyl)ethyl]oxy} quinoline;
or a pharmaceutically acceptable salt thereof.

5. (Original): A compound of claim 4 wherein the salt is the hydrochloride salt.

6. (Currently amended): A pharmaceutical composition which comprises a compound or a pharmaceutically acceptable salt as defined in claim 1 ~~any one of claims 1 to 5~~ and a pharmaceutically acceptable carrier or excipient.

7. (Currently amended): A compound or pharmaceutically acceptable salt as defined in claim 1 ~~any one of claims 1 to 5~~ for use in the treatment of depression, anxiety, Alzheimers disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke.

8. (Cancelled).

9. (Currently amended): A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1 ~~any one of claims 1 to 5~~ for use in the treatment of depression, anxiety, Alzheimers disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke.

10. (Currently amended): A method of treating depression, anxiety, Alzheimers disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke which comprises administering a safe and therapeutically effective amount to a patient in need thereof of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1. ~~any one of claims 1 to 5.~~